Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 10/20 | 0.60 |
| ▸ | LPAR1 | Q92633 | 9/20 | 0.60 |
| ▸ | LPAR5 | Q9H1C0 | 4/20 | 0.58 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | LPAR2 | Q9HBW0 | 6/20 | 0.50 |
| ▸ | LPAR6 | P43657 | 3/20 | 0.50 |
| ▸ | LPAR4 | Q99677 | 3/20 | 0.50 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9346178 | 1.00 | LPAR3 (0.60) | LPAR3LPAR1LPAR5USP2LPAR2 | |
| SCHEMBL7549117 | 1.00 | LPAR3 (0.60) | LPAR3LPAR1LPAR5USP2LPAR2 | |
| SCHEMBL173661 | 0.98 | LPAR3 (0.58) | LPAR3LPAR1LPAR5USP2LPAR2 | |
| SCHEMBL87627 | 0.98 | LPAR3 (0.58) | LPAR3LPAR1LPAR5USP2LPAR2 | |
| SCHEMBL10566910 | 0.91 | LPAR3 (0.66) | LPAR3LPAR1LPAR5USP2LPAR2 | |
| SCHEMBL10563405 | 0.91 | LPAR3 (0.66) | LPAR3LPAR1LPAR5USP2LPAR2 | |
| SCHEMBL2126767 | 0.91 | LPAR3 (0.56) | LPAR3LPAR1LPAR5LPAR2 | |
| SCHEMBL4240007 | 0.91 | LPAR3 (0.56) | LPAR3LPAR1LPAR5LPAR2 | |
| SCHEMBL10566055 | 0.90 | LPAR3 (0.60) | LPAR3LPAR1LPAR5USP2LPAR2 | |
| SCHEMBL31252907 | 0.88 | ALDH1A1 (0.58) | LPAR3LPAR1LPAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5827831-A | Lipid nucleotide analog prodrugs for oral administration | NEXSTAR PHARMACEUTICALS, INC. (US) | 1998-10-27 | — | — | US | disclosed |
| US-5744592-A | IMPROVING THE BIOAVAILABILITY AND ABSORPTION OF A DRUG THROUGH THE DIGESTIVE TRACT BY COVALENTLY BONDING THE DRUG AND A 1-O-OR-S-ALKYL-SN-GLYCERO-3-PHOSPHATE | NEXSTAR PHARMACEUTICALS, INC. (US) | 1998-04-28 | — | — | US | disclosed |
| US-5484809-A | ANTITUMOR | VESTAR, INC. (US) | 1996-01-16 | — | — | US | disclosed |
| EP-0674529-A1 | LIPID PRODRUGS FOR ORAL ADMINISTRATION | NeXstar Pharmaceuticals, Inc. (US) | 1995-10-04 | — | — | EP | disclosed |
| US-5411947-A | converting drugs having suitable functional groups to 1-O-alkyl-, 1-O-acyl-, 1-S-acyl, and 1-S-alkyl-sn-glycero-3-phosphate derivatives; drugs such as AZT, cladribine, AICA-Riboside | VESTAR, INC. (US) | 1995-05-02 | — | — | US | disclosed |
| WO-1994013324-A1 | LIPID PRODRUGS FOR ORAL ADMINISTRATION | VESTAR, INC. (US) | 1994-06-23 | — | — | WO | disclosed |